Patent intelligence · US
US 10912751
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular dis…
Patent details — US 10912751
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 9, 2021
- Expiration
- Feb 4, 2041
- Applicant
- Esperion Therapeutics, Inc.
- Claims
- 13
- CPC classes
- A61K, A61K31/194, A61K31/20, A61K31/397
Quick answer
US 10912751 (Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease) is held by Esperion Therapeutics, Inc.. Status: granted. Granted Feb 9, 2021. Expires Feb 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Esperion Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/194, A61K31/20, A61K31/397, A61P, A61P3/06
More from Esperion Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404227
Methods of making bempedoic acid and compositions of the same
granted -
US 12398087
Methods of making bempedoic acid and compositions of the same
granted -
US 12344578
Salt forms of bempedoic acid and methods for using the same
granted -
US 11987548
Methods of making bempedoic acid and compositions of the same
granted -
US 11926584
Methods of making bempedoic acid and compositions of the same
granted -
US 11760714
Methods of making bempedoic acid and compositions of the same
granted -
US 11744816
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
granted -
US 11613511
Methods of making bempedoic acid and compositions of the same
granted
Frequently asked questions
What is US patent 10912751?
US 10912751 (Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease) is held by Esperion Therapeutics, Inc.. Status: granted. Granted Feb 9, 2021. Expires Feb 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10912751?
Esperion Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 55 pharmaceutical patents for this assignee.
When does US 10912751 expire?
Our index shows an expiration date of Feb 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.